Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.
A recent JAMA Oncology study highlights the power of the open-access model GenomeDx has pursued since launching its Decipher prostate cancer prognostic.
Cigna to Cover NanoString Prosigna Breast Cancer Test
The insurer is the latest to provide coverage for NanoString's gene expression-based breast cancer recurrence risk test.
Noridian Issues Favorable LCD for NanoString's Prosigna Breast Cancer Assay
The finalized guidance follows a similar favorable LCD from Medicare contractor Palmetto, enabling reimbursement for Prosigna in a total of 39 US states.
ESMO Clinical Practice Guidelines Recommend NanoString's Prosigna Assay
The clinical practice guidelines include the PAM50 gene expression signature, which the Prosigna Assay is based on, as a predictive tool for chemotherapy benefit.